China Sees Flurry Of Activity On Avastin
Innovent’s Biosimilar Bevacizumab Approved As Bio-Thera And Henlius Advance
Executive Summary
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.
You may also be interested in...
Henlius Gets Fourth Chinese Biosimilar With Bevacizumab Nod
Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.
China’s Tot Biopharm Secures First Antibody Approval With Avastin Biosimilar
After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.
Henlius’ Ophthalmic Bevacizumab Program Moves Ahead
Shanghai Henlius Biotech is planning to move forward with wet AMD trials for its bevacizumab biosimilar rival to Avastin following a nod from the US FDA.